<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753372</url>
  </required_header>
  <id_info>
    <org_study_id>Dutch Rivaroxaban CCS Registry</org_study_id>
    <nct_id>NCT04753372</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk</brief_title>
  <official_title>Effectiveness and Safety of Low Dose Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maatschap Cardiologie Zwolle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Diagram B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maatschap Cardiologie Zwolle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry to describe the impact in terms of effectiveness and safety of the combination&#xD;
      treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices&#xD;
      in a real-life Dutch patient population that are at high risk of ischemic events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a national multicentre (~15 sites), prospective, single-arm, observational&#xD;
      study in patients treated with rivaroxaban 2.5mg bid on top of ASA75-100mg OD (N=1000).&#xD;
      Female and male patients with a diagnosis of CCS and/or symptomatic PAD will be enrolled in&#xD;
      the (outpatient) clinic after the decision for treatment with rivaroxaban 2.5mg bid,&#xD;
      co-administered with acetylsalicylic acid has been made by the treating physician.&#xD;
&#xD;
      The primary effectiveness endpoint is a composite of:&#xD;
&#xD;
        -  Major Adverse Cardiac Events (MACE including stroke, cardiovascular mortality and&#xD;
           myocardial infarction)&#xD;
&#xD;
        -  Clinically driven coronary, peripheral or carotid revascularization&#xD;
&#xD;
        -  Stent thrombosis at one year&#xD;
&#xD;
      The primary safety endpoint is Major Bleeding at one year. These major bleeding complications&#xD;
      are analysed according to the International Society on Thrombosis and Haemostasis (ISTH)&#xD;
      criteria as a composite of fatal bleeding, symptomatic bleeding into a critical organ (such&#xD;
      as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial,&#xD;
      or intramuscular with compartment syndrome), bleeding causing a fall in haemoglobin level of&#xD;
      2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood&#xD;
      or red cells.&#xD;
&#xD;
      The secondary endpoints will be:&#xD;
&#xD;
        -  Occurrence (and date) of stroke&#xD;
&#xD;
        -  Occurrence (and date) of myocardial infarction&#xD;
&#xD;
        -  Occurrence (and date) of cardiovascular death&#xD;
&#xD;
        -  Occurrence (and date) of coronary revascularization procedures (PCI, CABG).&#xD;
&#xD;
        -  Occurrence (and date) of peripheral revascularization procedures.&#xD;
&#xD;
        -  Occurrence (and date) of carotid revascularization procedures.&#xD;
&#xD;
        -  Occurrence (and date) of minor bleeding complications (according to ISTH)&#xD;
&#xD;
      In addition, all bleeding events including minor bleedings according to ISTH definitions will&#xD;
      be reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Primary Outcome Measures</measure>
    <time_frame>one year</time_frame>
    <description>The primary efficacy endpoint is a composite of 1) Major Adverse Cardiovascular Events (MACE), which is a composite endpoint of cardiovascular mortality, myocardial infarction and stroke, 2) clinically driven coronary, peripheral or carotid revascularization, and 3) stent thrombosis, that will be reported at 1 year.&#xD;
The primary safety endpoint is major bleeding according to the International Society on Thrombosis and Haemostatsis (ISTH) criteria that will be reported at 1 year. It is a composite of 1) fatal bleeding, 2) symptomatic bleeding into a critical organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), 3) bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or 4) leading to transfusion of two or more units of whole blood or red cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures</measure>
    <time_frame>one year</time_frame>
    <description>The secondary efficacy and safety endpoint is the incidence of individual endpoints, that will be reported at 1 year:&#xD;
Occurrence (and date) of stroke&#xD;
Occurrence (and date) of myocardial infarction&#xD;
Occurrence (and date) of cardiovascular death&#xD;
Occurrence (and date) of coronary revascularization procedures (PCI, CABG).&#xD;
Occurrence (and date) of peripheral revascularization procedures.&#xD;
Occurrence (and date) of carotid revascularization procedures.&#xD;
Occurrence (and date) of minor bleeding complications (according to ISTH)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Coronary Artery Disease (CAD)</condition>
  <condition>Peripheral Arterial Disease (PAD)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 MG [Xarelto]</intervention_name>
    <description>rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD</description>
    <other_name>acetylsalicylic acid (ASA)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Female and male patients with a diagnosis of CCS and/or symptomatic PAD will be enrolled in&#xD;
        the (outpatient) clinic within 4 weeks after the decision for treatment with rivaroxaban&#xD;
        2x2.5mg plus ASA (75-100mg) has been made by the investigator (according to label&#xD;
        (indicated for the prevention of atherothrombotic events in adult patients with coronary&#xD;
        artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of&#xD;
        ischemic events)) and who consent to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (≥18 years) patient.&#xD;
&#xD;
          -  Diagnosis of CAD and/or PAD and high risk of ischemic events.&#xD;
&#xD;
               -  Patients at high risk of ischaemic events include the following:&#xD;
&#xD;
               -  CAD + PAD&#xD;
&#xD;
               -  CAD + Recurrent MI (Previous MI followed by second MI)&#xD;
&#xD;
               -  CAD + diabetes mellitus (all types)&#xD;
&#xD;
               -  CAD + chronic kidney disease with eGFR 30-59 ml/min/1.73 m2 (CKD-EPI formula)&#xD;
&#xD;
               -  CAD + heart failure (ejection fraction ≥30% - 50%) and New York Heart Association&#xD;
                  (NYHA) class I or II;)&#xD;
&#xD;
          -  Treatment according to local marketing authorization, with rivaroxaban 2.5 mg [BID]&#xD;
             and ASA started prior to enrolment in the study.&#xD;
&#xD;
          -  Patients who are willing to participate in this study (signed informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hypersensitivity/allergy and known contraindication to ASA or rivaroxaban&#xD;
&#xD;
          -  Patients with recent major bleeding, active bleeding, or history with:&#xD;
&#xD;
               -  History of major clinical bleeding or known coagulopathy&#xD;
&#xD;
               -  History of intracerebral mass, aneurysm, arteriovenous malformation, or&#xD;
                  hemorrhagic stroke&#xD;
&#xD;
               -  Known severe liver dysfunction&#xD;
&#xD;
          -  Patients that have received any organ transplant or await any organ transplant&#xD;
&#xD;
          -  Patient with anemia (Hb &lt; 6.0 mmol/L)&#xD;
&#xD;
          -  Patient with active malignancy&#xD;
&#xD;
          -  Patients with eGFR &lt; 30 ml/min/1.73m2 or undergoing dialysis&#xD;
&#xD;
          -  Patients with liver failure accompanied with coagulopathy ( incl. Child-Pugh B and C)&#xD;
&#xD;
          -  Patients with concomitant use of other anticoagulants or antiplatelet drugs&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Patients currently participating in another investigational drug or drug-coated device&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rik Hermanides, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jolanda Pol-van der Velde, MSc</last_name>
    <phone>+31 (0)38 426 2999</phone>
    <email>jo.pol@diagram-zwolle.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Riezebos, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jawed Polad, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Jan van der Heijden, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samer Somi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clemens von Birgelen, MD, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medical Center</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saman Rasoul, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Arnoud van 't Hof, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken, location Meppel</name>
      <address>
        <city>Meppel</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Hoogslag, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jurriën Ten Berg, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Tweesteden hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Magro, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VieCuri</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eliza Kaplan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala hospital</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Hermanides, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Abi Selvarajah, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease (CAD)</keyword>
  <keyword>peripheral arterial disease (PAD)</keyword>
  <keyword>high ischemic risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

